BioMarin Pharmaceutical Inc. has entered into a definitive Settlement and License Agreement with Ascendis Pharma A/S, resolving all pending patent litigation between the companies. The agreement grants Ascendis a non-exclusive, worldwide license for its product TransCon CNP in exchange for significant royalty payments to BioMarin.
Key Details
- Royalty Terms: BioMarin will receive a 20% royalty on annual U.S. net sales and an 18% royalty on annual net sales in the European Union, Brazil, and South Korea for the licensed products.
- Agreement Duration: The royalty term extends from the first commercial sale in each respective territory until May 2030.
- Litigation Resolution: The agreement includes the dismissal of all pending patent-related litigation between the two companies.
- Effective Date: The agreement was signed on September 24, 2026, and is effective retroactively to August 28, 2026.